Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2003-11-21
2011-12-27
Saidha, Tekchand (Department: 1652)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C435S206000
Reexamination Certificate
active
08084036
ABSTRACT:
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of the target cell by a pathogen, such as a virus. Preferred target cells are epithelial cells. The invention provides compositions and methods for preventing viral diseases, such as influenza, using compounds having anchoring domains that can bind target cells linked to enzymatic activities that can act extracellularly to interfere with viral infection of target cells. The invention also provides compositions and methods for preventing viral diseases such as influenza using compounds having anchoring domains that can bind target cells linked to protease inhibitors that can act extracellularly to interfere with viral infection of target cells.
REFERENCES:
patent: 3439089 (1969-04-01), Cherkas
patent: 5532215 (1996-07-01), Lezdey et al.
patent: 5643758 (1997-07-01), Guan et al.
patent: 6251392 (2001-06-01), Hein et al.
patent: 6440419 (2002-08-01), Hein et al.
patent: 6737511 (2004-05-01), Youle et al.
patent: 6855801 (2005-02-01), San Antonio et al.
patent: 2002/0025320 (2002-02-01), Boyaka et al.
patent: 2005/0112751 (2005-05-01), Fang et al.
patent: 2007/0190163 (2007-08-01), Malaknov et al.
patent: 2008/0075708 (2008-03-01), Yu et al.
patent: 2009/0142327 (2009-06-01), Fang et al.
patent: WO93/03708 (1993-03-01), None
patent: WO98/31817 (1998-07-01), None
patent: 2004/047735 (2004-06-01), None
patent: WO 2004/047735 (2004-06-01), None
patent: 2006/031291 (2006-03-01), None
patent: WO 2006/031291 (2006-03-01), None
Benet et al., pp. 3-32, in Pharmacological Basis of Therapeutics, 8th ed., 1990, p. 1-32.
Achyuthan, KE and Achyuthan AM. 2001. Comparative enzymology, biochemistry and pathophysiology of human exo-a-sialidases (neuraminidases). Comparative Biochem & Physiol part B 129:29-64.
Air, GM and Laver, WG. 1995. Red cells bound to influenza virus N9 neuraminidase are not released by the N9 neuraminidase activity. Virology 211:278-284.
Auerswald EA, Horlein D, Reinhardt G, Schroder W and Schnabel E. 1988. Expression, isolation and characterization of recombinant [Arg15, Glu52] Aprotinin. Biol Chem Hoppe Seyler vol. 369, Suppl., pp. 27-35.
Barbey-Morel CL, Oeltmann TN, Edwards KM and Wright PF. 1987. Role of respiratory tract proteases in infectivity of influenza A virus. J Infect Dis 155:667-672.
Bessette PH, Aslund F, Beckwith J and Georgiou G. 1999. Efficient folding of proteins with multiple disulfide bonds' in theEscherichia colicytoplasm. Pro Natl Acad Sci USA 96:13703-13708.
Callan RJ, Hartmann FA, West SE and Hinshaw VS. 1997. Cleavage of influenza a virus H1 hemagglutinin by swine respiratory bacterial proteases. J Virol 71:7579-7585.
Connor, RJ, Kawaoka, Y, Webster, RG and Paulson JC. 1994. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205:17-23.
Copley, RR, Russell, RB and Ponting, CP. 2001. Sialidase-like Asp-boxes: sequence-similar structures within different protein folds. Prot Sci 10:285-292.
Corfield, AP, Veh, RW, Wember, M, Michalski, JC and Schauer, R. 1981. The release of N-acetyl- and N-glycolloyl-neuraminic acid from soluble complex carbohydrates and erythrocytes by bacterial, viral and mammalian sialidases. Bichem J 197:293-299.
Drzeniek, R. Substrate specificity of neuraminidases. 1973. Histochem J 5:271-290.
Endo Y, Carroll KN, Ikizler MR and Wright PF. 1996. Growth of influenza virus in primary, differentiated epithelial cells derived from adenoids. J Virol 70:2055-2058.
Fritz H and Wunderer G. 1983. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim-Forsch 33:479-494.
Fukudome, K., Yoshie, O. and Konno, T. 1989. Comparison of human, simian, and bovine rotaviruses for requirement of sialic acid in hemagglutination and cell adsorption. Virology 172:196-205.
Garten W, Bosch FX, Linder D, Rott R and Klenk HD. 1981. Proteolytic activation of the influenza virus hemagglutinin: the structure of the cleavage site and the enzymes involved in cleavage. Virology 115:361-374.
Goger, B, Halden, Y, Rek, A, Mosl, R, Pye, D, Gallagher, J and Kungl, AJ. 2002. Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Bichem 41:1640-1646.
Gotoh B, Ogasawara T, Toyoda T, Inocencio N, Hamaguchi M and Nagai Y. 1990. An endoprotease homologous to the blood clotting factor X as a determinant of viral tropism in chick embryo. EMBO J 9:4189-4195.
Gust, ID, Hampson, AW. and Lavanchy, D. 2001. Planning for the next pandemic. Rev Med Virol 11:59-70.
Hayden, FG. 1996. Amantadine and rimantadine-mechanisms. In Antiviral drug resistance (ed. D. D. Richman), pp. 59-77. Chichester, UK: John Wiley & Sons Ltd.
Hosoya M, Matsuyama S, Baba M, Susuki H and Shigeta S. 1992. Effects of protease inhibitors on replication of various myxoviruses. Antimicrobial Agents and Chemotherapy 36:1432-1436.
Ito, T. 2000. Interspecies transmission and receptor recognition of influenza a virus. Microbiol Immunol 44 (6) :423-430.
Janakiraman, MN, White, CL, Laver, WG, Air, GM and Luo, M. 1994. Structure of influenza virus neuraminidase B/lee/40 complexed with sialic acid and a dehydro analog at 1.8-A resolution: implications for the catalytic mechanism. Biochemistry 33:8172-8179.
Kido, H, Niwa, Y, Beppu, Y and Towatari, T. 1996. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and sendai virus. Advan Enzyme Regul 36:325-347.
Klenk, HD and Rott, R. 1988. The molecular biology of influenza virus pathogenicity. Adv Vir Res 34:247-281.
Klenk, HD and Garten W. 1994. Host cell proteases controlling virus pathogenicity. Trend Micro 2:39-43.
Kreisel, W, Volk, BA, Buchsel, R. and Reutter, W. 1980. Different half-lives of the carbohydrate and protein moieties of a 110,000-dalton glycoproteins isolated from plasma membranes of rat liver. Proc Natl Acad Sci USA 77:1828-1831.
Krunkosky TM, Fischer BM, Martin LD, Jones N, Akley NJ and Adler KB. 2000. Effects of TNF-b on expression of ICAM-1 in human airway epithelial cells in vitro. Am J Respir Cell Mol Biol. 22:685-692.
Lazarowitz SG, Goldberg AR and Choppin PW. 1973. Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: host cell activation of serum plasminogen. Virology 56:172-180.
Lee, MK and Lander, AD. 1991. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. Pro Natl Acad Sci USA 88:2768-2772.
Meltzer, MI, Cox, NJ and Fukuda, K. 1999. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 5:659-671.
Meyer, FA, King, M and Gelman, RA., 1975. On the role of sialic acid in the rheological properties of mucus. Biochimica et Biophysica Acta 392: 223-232.
Milner, CM, Smith, SV, Carrillo MB, Taylor, GL, Hollinshead, M and Campbell, RD. 1997. Identification of a sialidase encoded in the human major histocompatibility complex. J Bio Chem 272:4549-4558.
Monti, E, Preti, A, Venerando, B and Borsani, G. 2002. Recent development in mammalian sialidase molecular biology. Neurochem Res 27:646-663.
Monti, E, Preti, A, Nesti, C, Ballabio, A and Borsani G. 1999. Expression of a novel human sialidase encoded by the NEU2 gene. Glycobiol 9:1313-1321.
Monti, E, Bassi, MT, Papini, N, Riboni, M, Manzoni, M, Veneranodo, B, Croci, G, Preti, A, Ballabio, A, Tettamanti, G and Borsani, G. 2000. Identification and expression of NEU3, a novel human sialidase associated to the plasma membrane. Bichem J 349:343-351.
Murakami M, Towatari T, Ohuchi M, Shiota M, Akao M, Okumura Y, Parry MA and Kido H. 2001. Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai v
Fang Fang
Malakhov Michael
Yu Mang
Fish & Richardson P.C.
NexBio, Inc.
Saidha Tekchand
LandOfFree
Broad spectrum anti-viral therapeutics and prophylaxis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Broad spectrum anti-viral therapeutics and prophylaxis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Broad spectrum anti-viral therapeutics and prophylaxis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297117